Debottlenecking R&D with Automated Powder Dispensing

contributed by Mettler Toledo | 09/24/2018

The Enabling Technologies Consortium™ (ETC) - group of major pharmaceutical and biotechnology companies - has published a new study on powder dispensing with the aim of easing R&D bottlenecks, particularly in high-throughput experimentation.

In an effort to understand the relative merits and disadvantages of existing automated powder dispensing technologies, an independent evaluation was carried out by the ETC's High Throughput Experimentation (HTE) working group. This working group comprised of AstraZeneca (AZ), Bristol-Myers Squibb (BMS), GlaxoSmithKline (GSK), Merck & Co., and Pfizer. The study evaluated four commercially available automated powder dispensing platforms, including Quantos from METTLER TOLEDO, to assess their abilities to accurately weigh a wide range of different powder types into vials.

The results of this benchmarking study, entitled "Collaborative Evaluation of Commercially Available Automated Powder Dispensing Platforms for High Throughput Experimentation in Pharmaceutical Applications", were presented at Pittcon 2018 [1] and will be published in OPRD [2].

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.